Spyre Therapeutics (NASDAQ:SYRE) Now Covered by Analysts at Robert W. Baird

Robert W. Baird began coverage on shares of Spyre Therapeutics (NASDAQ:SYRE) in a report released on Thursday, Marketbeat reports. The brokerage issued an outperform rating and a $50.00 price target on the stock.

Several other equities analysts have also recently weighed in on SYRE. Wells Fargo & Company upgraded Spyre Therapeutics from an equal weight rating to an overweight rating and raised their price objective for the company from $12.00 to $35.00 in a research note on Friday, March 1st. Stifel Nicolaus increased their price objective on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the company a buy rating in a research note on Tuesday, March 26th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $41.00.

Spyre Therapeutics Stock Performance

Shares of SYRE stock opened at $35.78 on Thursday. Spyre Therapeutics has a fifty-two week low of $2.66 and a fifty-two week high of $47.97. The business has a 50 day simple moving average of $36.20. The company has a market capitalization of $1.29 billion, a P/E ratio of -0.48 and a beta of 2.93.

Spyre Therapeutics (NASDAQ:SYRE) last released its earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($1.80). On average, research analysts predict that Spyre Therapeutics will post -2.36 EPS for the current year.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).